{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:39:33Z","timestamp":1790800773875,"version":"4.1.0"},"reference-count":42,"publisher":"MDPI AG","issue":"16","license":[{"start":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T00:00:00Z","timestamp":1754956800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"\u201cPI22\/01944 del ISCIII\u201d","award":["CB16\/11\/00374"],"award-info":[{"award-number":["CB16\/11\/00374"]}]},{"name":"CIBERCV","award":["CB16\/11\/00374"],"award-info":[{"award-number":["CB16\/11\/00374"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background\/Objectives: Chronic kidney disease (CKD) is a significant risk factor for thrombogenic and bleeding events in patients with atrial fibrillation (AF). Left atrial appendage occlusion (LAAO) is increasingly utilized as an alternative to oral anticoagulation. We aimed to compare LAAO against medical therapy in advanced CKD patients (A-CKD). Methods: We conducted a retrospective cohort study to compare patients with AF who had undergone LAAO (intervention group) or patients receiving oral anticoagulation (OAC) (control group). All of them had the diagnosis of A-CKD (estimated glomerular filtration rate (eGFR) &lt; 30 mL\/min\/1.73 m2). The primary endpoint was a composite of stroke, transient ischemic attack (TIA), systemic embolism (SE), and major bleeding. Secondary endpoints included: an efficacy combined endpoint (a composition of stroke, TIA, and SE); major bleedings (defined as Bleeding Academic Research Consortium (BARC) \u2265 3), and mortality at follow-up. A propensity score matching was used to balance the populations. Results: In total, 81 and 102 patients composed the LAAO and anticoagulation groups. Mean age was 78.27 \u00b1 10.3 and 81.2 \u00b1 9.07 (p = 0.069) and female sex was 38.3% and 44.1%, respectively. Patients who underwent LAAO had a higher HAS-BLED score: 3.46 \u00b1 0.85 vs. 3.77 \u00b1 1.06, p = 0.011. Median follow-up was 19.0 months [IQR: 10.9\u201333.5]. There were no differences in the primary combined endpoint at 3-years follow-up\u201422.2% vs. 34.2% (hazard ratio (HR) 0.63, CI-95%: 0.353\u20131.11, p = 0.102)\u2014nor respecting the efficacy combined endpoint: 3.7% vs. 6.9% (HR 0.54, CI-95%: 0.14\u20132.09, p = 0.355). Patients under anticoagulation treatment did present major bleedings (BARC \u2265 3) more often than the intervention group: 38.3%vs50% (HR 0.52, CI-95%: 0.28\u20130.96, p = 0.031). A total of 15 patients (14.7%) from the control group underwent LAAO during follow-up. After a propensity score matching analysis, the primary combined endpoint was more frequent in the control group (HR 0.47, CI-95%: 0.25\u20130.90, p = 0.019). Conclusions: Compared with oral anticoagulation therapy, LAAO had no differences in efficacy, but fewer major bleeding rates were found.<\/jats:p>","DOI":"10.3390\/jcm14165709","type":"journal-article","created":{"date-parts":[[2025,8,12]],"date-time":"2025-08-12T16:30:36Z","timestamp":1755016236000},"page":"5709","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Left Atrial Appendage Occlusion Compared to Anticoagulation in Patients Suffering from Atrial Fibrillation with Advanced Chronic Kidney Disease"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6462-4061","authenticated-orcid":false,"given":"Sergio","family":"L\u00f3pez-Tejero","sequence":"first","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0573-4321","authenticated-orcid":false,"given":"Pablo","family":"Ant\u00fanez-Mui\u00f1os","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0715-6553","authenticated-orcid":false,"given":"Pilar","family":"Fraile-G\u00f3mez","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6320-0163","authenticated-orcid":false,"given":"Fabi\u00e1n","family":"Blanco-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gilles","family":"Barreira-de Sousa","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jes\u00fas","family":"Herrero-Garibi","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Rodr\u00edguez-Collado","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alejandro","family":"Diego-Nieto","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Candelas","family":"P\u00e9rez del Villar","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gonzalo C.","family":"Delgado-Lapeira","sequence":"additional","affiliation":[{"name":"Servicio de Nefrolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), 37007 Salamanca, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Mart\u00edn-Moreiras","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pedro L.","family":"S\u00e1nchez-Fern\u00e1ndez","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9742-6072","authenticated-orcid":false,"given":"Ignacio","family":"Cruz-Gonz\u00e1lez","sequence":"additional","affiliation":[{"name":"Servicio de Cardiolog\u00eda, Complejo Asistencial Universitario de Salamanca (CAUSA), Universidad de Salamanca (USAL), 37007 Salamanca, Spain"},{"name":"Instituto de Investigaci\u00f3n Biom\u00e9dica de Salamanca (IBSAL), 37007 Salamanca, Spain"},{"name":"Centro de Investigaci\u00f3n Biom\u00e9dica en Red de Enfermedades Cardiovasculares (CIBER-CV), Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,12]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.1161\/CIR.0000000000000659","article-title":"Heart Disease and Stroke Statistics-2019 Update: A Report from the American Heart Association","volume":"139","author":"Benjamin","year":"2019","journal-title":"Circulation"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.jacc.2018.04.013","article-title":"Stroke Prevention in Nonvalvular Atrial Fibrillation: A Stakeholder Perspective","volume":"71","author":"Alkhouli","year":"2018","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Hill, N.R., Fatoba, S.T., Oke, J.L., Hirst, J.A., O\u2019Callaghan, C.A., Lasserson, D.S., and Hobbs, F.D. (2016). Global Prevalence of Chronic Kidney Disease\u2014A Systematic Review and Meta-Analysis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0158765"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1093\/cvr\/cvaa258","article-title":"Pathophysiology of atrial fibrillation and chronic kidney disease","volume":"117","author":"Ding","year":"2021","journal-title":"Cardiovasc. Res."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2825","DOI":"10.1681\/ASN.2015050535","article-title":"The risk of major hemorrhage with CKD","volume":"27","author":"Molnar","year":"2016","journal-title":"J. Am. Soc. Nephrol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus Warfarin in Patients with Atrial Fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1056\/NEJMoa1009638","article-title":"Rivaroxaban versus Warfarin in Nonvalvular Atrial Fibrillation","volume":"365","author":"Patel","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1056\/NEJMoa1107039","article-title":"Apixaban versus Warfarin in Patients with Atrial Fibrillation","volume":"365","author":"Granger","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus Warfarin in Patients with Atrial Fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N. Engl. J. Med."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"e202175","DOI":"10.1001\/jamanetworkopen.2020.2175","article-title":"Association Between Use of Warfarin for Atrial Fibrillation and Outcomes Among Patients With End-Stage Renal Disease: A Systematic Review and Meta-analysis","volume":"3","author":"Randhawa","year":"2020","journal-title":"JAMA Netw. Open."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1093\/ckj\/sfad004","article-title":"Direct oral anticoagulants versus warfarin in patients with non-valvular atrial fibrillation and CKD G3-G5D","volume":"16","author":"Welander","year":"2023","journal-title":"Clin. Kidney J."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1161\/CIRCULATIONAHA.122.062779","article-title":"A Randomized Controlled Trial Comparing Apixaban with the Vitamin K Antagonist Phenprocoumon in Patients on Chronic Hemodialysis: The AXADIA-AFNET 8 Study","volume":"147","author":"Reinecke","year":"2023","journal-title":"Circulation"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1161\/CIRCULATIONAHA.121.054990","article-title":"Apixaban for Patients with Atrial Fibrillation on Hemodialysis: A Multicenter Randomized Controlled Trial","volume":"146","author":"Pokorney","year":"2022","journal-title":"Circulation"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/S0140-6736(09)61343-X","article-title":"Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: A randomised non-inferiority trial","volume":"374","author":"Holmes","year":"2009","journal-title":"Lancet"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2014.04.029","article-title":"Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial","volume":"64","author":"Price","year":"2014","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/0003-4975(95)00887-X","article-title":"Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation","volume":"61","author":"Blackshear","year":"1996","journal-title":"Ann. Thorac. Surg."},{"key":"ref_17","first-page":"223","article-title":"Assessment of left atrial appendage function by transesophageal echocardiography","volume":"84","author":"Pollick","year":"1991","journal-title":"Implic. Dev. Thrombus. Circulation"},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"205","DOI":"10.5603\/CJ.a2020.0036","article-title":"Risk of left atrial appendage thrombus in patients with atrial fibrillation and chronic kidney disease","volume":"29","author":"Budnik","year":"2022","journal-title":"Cardiol. J."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.amjcard.2020.12.081","article-title":"Effect of Glomerular Filtration Rates on Outcomes Following Percutaneous Left Atrial Appendage Closure","volume":"145","author":"Faroux","year":"2021","journal-title":"Am. J. Cardiol."},{"key":"ref_20","first-page":"499","article-title":"Left atrial appendage occlusion in patients suffering from advanced chronic kidney disease (stage 4 and 5). Long-term follow-up","volume":"103","author":"Sousa","year":"2024","journal-title":"Catheter. Cardiovasc. Interv."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"3122","DOI":"10.1016\/j.jacc.2020.04.067","article-title":"Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients with Atrial Fibrillation","volume":"75","author":"Osmancik","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1503","DOI":"10.1016\/j.jacc.2019.12.040","article-title":"The NCDR Left Atrial Appendage Occlusion Registry","volume":"75","author":"Freeman","year":"2020","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jacc.2021.10.023","article-title":"4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation","volume":"79","author":"Osmancik","year":"2022","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijcard.2016.01.003","article-title":"Impact of chronic kidney disease on left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation","volume":"207","author":"Kefer","year":"2016","journal-title":"Int. J. Cardiol."},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"Stanifer, J.W., Pokorney, S.D., Chertow, G.M., Hohnloser, S.H., Wojdyla, D.M., Garonzik, S., Byon, W., Hijazi, Z., Lopes, R.D., and Alexander, J.H. (2020). Apixaban Versus Warfarin in Patients with Atrial Fibrillation and Advanced Chronic Kidney Disease. Circulation, 1384\u20131392.","DOI":"10.1161\/CIRCULATIONAHA.119.044059"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1007\/s40620-020-00774-5","article-title":"Outcomes on safety and efficacy of left atrial appendage occlusion in end stage renal disease patients undergoing dialysis","volume":"34","author":"Genovesi","year":"2021","journal-title":"J. Nephrol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1093\/eurheartj\/ehr488","article-title":"Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: The Swedish Atrial Fibrillation cohort study","volume":"33","author":"Friberg","year":"2012","journal-title":"Eur. Heart J."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"euad315","DOI":"10.1093\/europace\/euad315","article-title":"Prognostic value of chronic kidney disease in patients undergoing left atrial appendage occlusion","volume":"25","author":"Magnocavallo","year":"2023","journal-title":"Europace"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1007\/s10557-021-07144-8","article-title":"Effect of Rivaroxaban or Apixaban in Atrial Fibrillation Patients with Stage 4\u20135 Chronic Kidney Disease or on Dialysis","volume":"35","author":"Chen","year":"2021","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"h246","DOI":"10.1136\/bmj.h246","article-title":"The association between kidney function major bleeding in older adults with atrial fibrillation starting warfarin treatment: Population based observational study","volume":"350","author":"Jun","year":"2015","journal-title":"Br. Med. J."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1016\/j.amjmed.2016.03.024","article-title":"Major Outcomes in Atrial Fibrillation Patients with One Risk Factor: Impact of Time in Therapeutic Range Observations from the SPORTIF Trials","volume":"129","author":"Proietti","year":"2016","journal-title":"Am. J. Med."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1093","DOI":"10.1378\/chest.10-0134","article-title":"A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: The euro heart survey","volume":"138","author":"Pisters","year":"2010","journal-title":"Chest"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2894","DOI":"10.1093\/eurheartj\/ehaa169","article-title":"Left atrial appendage occlusion with the Amplatzer\u2122 Amulet\u2122 device: Full results of the prospective global observational study","volume":"41","author":"Landmesser","year":"2020","journal-title":"Eur. Heart J."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Luani, B., Genz, C., Herold, J., Mitrasch, A., Mitusch, J., Wiemer, M., Schmei\u00dfer, A., Braun-Dullaeus, R.C., and Rauwolf, T. (2019). Cerebrovascular events, bleeding complications and device related thrombi in atrial fibrillation patients with chronic kidney disease and left atrial appendage closure with the WATCHMANTM device. BMC Cardiovasc. Disord., 19.","DOI":"10.1186\/s12872-019-1097-0"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/j.nefro.2021.02.008","article-title":"Impacto pron\u00f3stico de la enfermedad renal cr\u00f3nica sobre el cierre percut\u00e1neo de la orejuela izquierda en la fibrilaci\u00f3n auricular: Una experiencia unic\u00e9ntrica","volume":"42","author":"Regueiro","year":"2022","journal-title":"Nefrolog\u00eda"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.ahj.2020.01.010","article-title":"Rivaroxaban versus warfarin in patients with nonvalvular atrial fibrillation and stage IV\u2013V chronic kidney disease","volume":"223","author":"Weir","year":"2020","journal-title":"Am. Heart J."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"125","DOI":"10.2215\/CJN.06430518","article-title":"Demystifying the benefits and harms of anticoagulation for atrial fibrillation in chronic kidney disease","volume":"14","author":"Garlo","year":"2019","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.2215\/CJN.13811217","article-title":"Risks and Benefits of Direct Oral Anticoagulants across the Spectrum of GFR among Incident and Prevalent Patients with Atrial Fibrillation","volume":"13","author":"Shin","year":"2018","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"1030","DOI":"10.1001\/jama.2015.10725","article-title":"Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients with Heart Failure with and Without Atrial Fibrillation","volume":"314","author":"Melgaard","year":"2015","journal-title":"JAMA"},{"key":"ref_40","doi-asserted-by":"crossref","unstructured":"Abouzid, M.R., Kamel, I., Saleh, A., Vidal Margenat, A., and Hariharan, R. (2024). Assessing Stroke and Mortality Risk in Heart Failure: The CHA2DS2-VASc Score\u2019s Prognostic Value in Patients with and Without Atrial Fibrillation: A Meta-Analysis. Cardiol. Rev.","DOI":"10.1097\/CRD.0000000000000749"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.amjmed.2010.05.007","article-title":"Implications of the CHA(2)DS(2)-VASc and HAS-BLED Scores for thromboprophylaxis in atrial fibrillation","volume":"124","author":"Lip","year":"2011","journal-title":"Am. J. Med."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1056\/NEJMra2201153","article-title":"Uses of GFR and Albuminuria Level in Acute and Chronic Kidney Disease","volume":"386","author":"Levey","year":"2022","journal-title":"N. Engl. J. Med."}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5709\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:25:45Z","timestamp":1760034345000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/14\/16\/5709"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,12]]},"references-count":42,"journal-issue":{"issue":"16","published-online":{"date-parts":[[2025,8]]}},"alternative-id":["jcm14165709"],"URL":"https:\/\/doi.org\/10.3390\/jcm14165709","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,12]]}}}